1. Home
  2. TBBK vs NVAX Comparison

TBBK vs NVAX Comparison

Compare TBBK & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TBBK
  • NVAX
  • Stock Information
  • Founded
  • TBBK 1999
  • NVAX 1987
  • Country
  • TBBK United States
  • NVAX United States
  • Employees
  • TBBK N/A
  • NVAX N/A
  • Industry
  • TBBK Major Banks
  • NVAX Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • TBBK Finance
  • NVAX Health Care
  • Exchange
  • TBBK Nasdaq
  • NVAX Nasdaq
  • Market Cap
  • TBBK 2.7B
  • NVAX 2.0B
  • IPO Year
  • TBBK 2004
  • NVAX 1995
  • Fundamental
  • Price
  • TBBK $50.51
  • NVAX $9.76
  • Analyst Decision
  • TBBK Buy
  • NVAX Buy
  • Analyst Count
  • TBBK 3
  • NVAX 6
  • Target Price
  • TBBK $55.00
  • NVAX $17.83
  • AVG Volume (30 Days)
  • TBBK 564.7K
  • NVAX 7.2M
  • Earning Date
  • TBBK 10-24-2024
  • NVAX 11-07-2024
  • Dividend Yield
  • TBBK N/A
  • NVAX N/A
  • EPS Growth
  • TBBK 16.52
  • NVAX N/A
  • EPS
  • TBBK 3.95
  • NVAX N/A
  • Revenue
  • TBBK $472,015,000.00
  • NVAX $987,667,000.00
  • Revenue This Year
  • TBBK N/A
  • NVAX N/A
  • Revenue Next Year
  • TBBK $7.05
  • NVAX N/A
  • P/E Ratio
  • TBBK $12.71
  • NVAX N/A
  • Revenue Growth
  • TBBK 6.71
  • NVAX N/A
  • 52 Week Low
  • TBBK $29.92
  • NVAX $3.53
  • 52 Week High
  • TBBK $59.26
  • NVAX $23.86
  • Technical
  • Relative Strength Index (RSI)
  • TBBK 44.27
  • NVAX 36.20
  • Support Level
  • TBBK $45.82
  • NVAX $9.52
  • Resistance Level
  • TBBK $59.26
  • NVAX $10.63
  • Average True Range (ATR)
  • TBBK 2.17
  • NVAX 0.57
  • MACD
  • TBBK -0.96
  • NVAX -0.12
  • Stochastic Oscillator
  • TBBK 35.86
  • NVAX 9.97

About TBBK The Bancorp Inc

The Bancorp Inc is a financial holding company, through its subsidiary it is engaged in specialty lending namely securities-backed lines of credit, vehicle fleet and another equipment leasing, Small Business Administration lending, insurance policy cash value-backed lines of credit and commercial mortgage-backed loans, generated for sale into commercial mortgage-backed securities markets through securitizations. The company deposits and non-interest income are generated in the payments business which consists of issuing, acquiring, and automated clearing house accounts.

About NVAX Novavax Inc.

Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. Novavax works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The Company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from Europe.

Share on Social Networks: